Showing results (31-40 of 137) with videos related to
Sort By:
Pageof 14
Targeted Oncology|August 5, 2020
Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with CabozantinibTomas Buchler, Marie Kopecka, Anezka Zemankova, et al.Targeted Oncology|April 16, 2015
The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective StudyOndrej Fiala, Jindrich Finek, Tomas Buchler, et al.Journal of Cancer Research and Clinical Oncology|March 17, 2024
A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatmentsIva Benesova, Linda Capkova, Andrej Ozaniak, et al.Clinical Lymphoma & Myeloma|May 2, 2009
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomibLudek Pour, Zdenek Adam, Lucie Buresova, et al.Urologic Oncology|March 18, 2014
Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysisTomas Buchler, Zbynek Bortlicek, Alexandr Poprach, et al.The Hematology Journal : the Official Journal of the European Haematology Association|February 5, 2005
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapyTomas Buchler, Marta Krejci, Adam Svobodnik, et al.Journal of Cancer|December 7, 2018
The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First LineOndrej Fiala, Petr Hosek, Ondrej Sorejs, et al.Advances in Therapy|January 29, 2019
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRCHolger Hebart, Michael Kiehl, Jiri Tomasek, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 20, 2015
High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinibOndrej Fiala, Milos Pesek, Jindrich Finek, et al.Cancers|April 2, 2020
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 PatientsOndrej Fiala, Jindrich Finek, Alexandr Poprach, et al.Pageof 14